.jpeg)
2026-03-12 07:23:51
ARID1A is a key subunit of the SWI/SNF chromatin remodeling complex, with mutations linked to various cancers. Recent research reveals ARID1A deficiency triggers viral mimicry, enhancing tumor immunogenicity and providing new immunotherapy targets.
2026-03-12 06:53:06
Alectinib is a second-generation ALK inhibitor for treating ALK-positive advanced non-small cell lung cancer. This article comprehensively analyzes its first and second-line treatment efficacy, brain metastasis control, resistance issues, and safety profile for patients and healthcare professionals.
2026-03-12 05:06:31
Mavacamten (brand name Maifantuo), the first oral cardiac myosin inhibitor, targets obstructive hypertrophic cardiomyopathy (HCM) by curbing excessive myocardial contraction. It improves left ventricular outflow tract (LVOT) obstruction via ATPase inhibition. This article details its mechanism, indications, dosing, monitoring, and long-term management, emphasizing personalized care.
2026-03-12 03:31:19
Remibrutinib (brand name Ruipoduo) is a highly selective Bruton's tyrosine kinase (BTK) inhibitor for chronic spontaneous urticaria. Clinical studies show good safety and tolerability, with common side effects including headache and gastrointestinal reactions. Infection prevention, hematological monitoring, and long-term follow-up are key.
2026-03-11 07:15:54
Repotrectinib, as a next-generation ROS1/NTRK tyrosine kinase inhibitor, has attracted significant attention regarding its generational classification. This article professionally analyzes Repotrectinib's generation positioning, core characteristics, and treatment sequence based on the development history of ROS1 inhibitors.
2026-03-10 05:17:26
Brigatinib as a targeted therapy demonstrates significant efficacy in treating Neurofibromatosis Type 2 (NF2), capable of reducing tumor volume and improving hearing function, providing new hope for patients unable to benefit from surgery or radiation.
2026-03-10 01:38:34
Goserelin, as a GnRH analog, is widely used for prostate cancer, breast cancer, and gynecological diseases, but may cause side effects like hot flashes and bone density loss. 2025 clinical guidelines recommend light, nutritious, balanced diet with high protein and calcium, avoiding spicy and processed foods. Special populations need personalized management to enhance treatment tolerance and quality of life.
2026-03-10 01:22:25
Breakthrough research published in "Genes & Immunity" (2025) identifies folate metabolism-related gene CYP26A1 as a clinical immune target for colorectal cancer. Multi-omics analysis and experimental validation reveal CYP26A1's role in promoting tumor proliferation, metastasis, and immunosuppressive microenvironment, offering new precision treatment directions for patients.
2026-03-06 05:41:28
Decoding Inavolisib’s breakthrough in PIK3CA-mutant HR+/HER2- breast cancer: INAVO120 trial data, quality-of-life preservation, and expansion to HER2+ disease.
2026-03-06 05:19:40
Compare Romiplostim (subcutaneous) and Eltrombopag (oral) for ITP, highlighting administration, onset time, side effects, and clinical decision factors to optimize personalized therapy.
2026-03-06 04:55:21
Decoding asciminib (Asciminib)'s targeting of the ABL myristoyl pocket, its breakthrough role in treating CML resistance, pharmacokinetics, and clinical advantages for informed patient decisions.
2026-03-06 04:15:06
Eplerenone is commonly prescribed for long-term management of hypertension and heart failure but requires regular monitoring of potassium and kidney function. This article analyzes its safety, necessity, and key precautions for sustained use.
